Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 16/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | ATXN2 | Q99700 | 9/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171685 | 0.93 | ENPP2 (0.86) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3048945 | 0.92 | ENPP2 (0.85) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3048946 | 0.92 | ENPP2 (0.85) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3053030 | 0.91 | ENPP2 (0.83) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3050762 | 0.91 | ENPP2 (0.83) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL171660 | 0.91 | ENPP2 (0.87) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3060510 | 0.91 | ENPP2 (0.83) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3055765 | 0.91 | ENPP2 (0.83) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3058186 | 0.90 | ENPP2 (0.82) | ENPP2KCNH2ATXN2GRIN2DGRIN3B | |
| SCHEMBL3054826 | 0.90 | ENPP2 (0.85) | ENPP2KCNH2ATXN2GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | claimed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | claimed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2426106-B1 | Piperidine and Piperazine derivatives for the treatment of tumours | MERCK PATENT GMBH (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2426106-A1 | Piperidine and Piperazine derivatives for the treatment of tumours | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009046841-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | ENPP2 3706/4885KCNH2 66/4885ATXN2 3403/4885 |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | ENPP2 3706/4885KCNH2 66/4885ATXN2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.